BME Renta Variable - Data of PHARMA MAR, S.A.

Date	Hour	Close	Ref.	% Dif.	Last	High	Low	Avg.	Volume	Turnover
18/06/2021	Close	77.3600	76.6200	0.97	77.3600	77.7000	74.5000	76.6190	116,959	8,961,275.88
17/06/2021	Close	76.6200	76.8000	-0.23	76.6200	76.8000	74.2400	75.5231	77,198	5,830,233.44

18/06/2021 17:37:13
Bid			Ask
Orders	Volume	Price	Price	Volume	Orders
2	947	77.3600	77.5000	940	2
5	2,038	77.3400	77.5200	112	1
2	207	77.3200	77.5600	252	2
4	2,376	77.3000	77.6000	112	1
1	305	77.2800	77.6200	377	2

Data Delayed 15 minutes.

1 year
5 years

Last pay

Type	Ex-date	Payment Date	Concept
Dividend	28/04/2021	30/04/2021	Annual 2020

Last split

Date	Equivalence

Last reverse split

Date	Equivalence
22/07/2020	1 x 12

Last capital increase

Period	Proportion	Type
02/06/2017	2 x 1,000	Premium

	2021 until 17/06	2020	2019	2018	2017
Capitalisation * (thousands of euros)	1,406,353	1,303,198	794,858	242,688	552,170
Shares (x 1,000)	18,355	18,355	222,649	222,649	222,649
Period Close Price (euros)	76.6200	71.0000	42.8400	13.0800	29.7600
Period Last Price (euros)	76.6200	71.0000	42.8400	13.0800	29.7600
Period High Price (euros)	120.0000	148.0000	46.1520	33.1440	51.0600
Period Low Price (euros)	71.5500	30.0000	12.9360	10.4520	24.4200
Volume (thousands of shares)	16,197	62,497	26,786	18,457	17,107
Turnover (thousands of euros)	1,558,512	4,893,224	650,774	348,611	654,106

Profile

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program.

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM60184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom and the United States.

PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova and Xylazel.

To learn more about PharmaMar, please visit us at www.pharmamar.com.

Source: Issuing company.

18/06/2021 00:11:41

Research

Morningstar - Quantitative Report (26 May 2021 08:16) (148 KB)

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.